MedTrace Logo

Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension

NCT00420342 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2015-06-02

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to compare the effects of treatment of two different formulations of Angeliq® and Prempro on blood pressure in post-menopausal women with prehypertension.

Conditions

Interventions

DRUG

Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)

SH K 00641 A -Active study medication encapsulated tablet

DRUG

Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)

SH K 00641 B - Active study medication encapsulated tablet

DRUG

SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)

Active control encapsulated tablet

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00420342 on ClinicalTrials.gov